Heterologous immunization with BNT162b2 followed by mRNA-1273 in dialysis patients: seroconversion and presence of neutralizing antibodies투석 환자에서 BNT162b2에 이어 mRNA-1273으로 이종 면역화: 혈청전환 및 중화항체 존재Article Published on 2022-05-252022-09-12 Journal: Nephrology, dialysis, transplantation : official p [Category] COVID19(2023년), MERS, SARS, 진단, [키워드] acute respiratory syndrome Analysis anti-SARS-CoV-2 antibodies antibody BNT162b2 boost booster Cambridge Characteristics Concentration coronavirus COVID-19 cut-off dialysis disease dose Efficacy Elasomeran Elecsy Genscript Germany heterologous immunization high risk Humoral immunity immunoreactivity Immunosuppression Infection Mainz Moderna Mortality mRNA vaccine mRNA-1273 mRNA-1273 booster neutralization Neutralization assay Neutralizing antibodies neutralizing antibody of BNT162b2 Patient patients performed plaque reduction neutralization PRNT receiver receiving renal replacement therapy ROC Roche Diagnostics SARS-CoV-2 SARS-CoV-2 spike Seroconversion surrogate Test the SARS-CoV-2 titre Tozinameran USA vaccination virus-neutralizing was measured was reduced were measured were used while wild-type SARS-CoV-2 York [DOI] 10.1093/ndt/gfac018 PMC 바로가기 [Article Type] Article
Human Milk Antibodies after BNT162b2 Vaccination Exhibit Reduced Binding against SARS-CoV-2 Variants of ConcernArticle Published on 2022-01-312022-10-28 Journal: Vaccines [Category] COVID-19, [키워드] anti-RBD IgA antibody Antibody binding Antibody Response approved Beta binding BNT162b2 breast milk antibodies Breastfeeding circulating collected Comirnaty concern COVID-19 COVID-19 vaccine cross-protection Delta delta variant different time point Gamma Human human milk IgA Immunity immunoglobin A individual Infants lactating women milk mother mucosal passive immunity Pfizer vaccination pre-vaccination raise RBD Receptor binding domain recommendation reduction in responses risk SARS-CoV-2 second dose severe disease significant level specificity Support Tozinameran transferred vaccination variants of concern VOCs Wuhan-Hu-1 [DOI] 10.3390/vaccines10020225 PMC 바로가기 [Article Type] Article
Incomplete Subacute Transverse Myelitis Following Vaccination With Pfizer-BioNTech COVID-19 mRNA Vaccine: A Case ReportNeurology Published on 2021-12-162022-10-31 Journal: Cureus [Category] COVID-19, [키워드] adverse effect adverse event Algorithm approval approved association benefit BNT162b2 Brain Case report clinical testing clinical trial coronavirus disease Course COVID-19 COVID-19 vaccine demonstrated detect disorder distribution Efficacy elevated first dose Health healthy humans IgG imperative improvement Incomplete Inflammatory Methylprednisolone MRI mRNA mRNA vaccination mRNA vaccine Myelitis occurred pandemic Patient Pfizer-BioNTech Pfizer-BioNTech COVID-19 vaccine positive potential risk receiving Regulatory report required saddle anesthesia Stage Subacute Surveillance Symptoms temperature the vaccine Tozinameran Transverse transverse myelitis Treatment vaccination vaccination against COVID-19 Vaccinations Vaccine with COVID-19 [DOI] 10.7759/cureus.20460 PMC 바로가기 [Article Type] Neurology
Difference in the lipid nanoparticle technology employed in three approved siRNA (Patisiran) and mRNA (COVID-19 vaccine) drugs3 개의 승인 된 siRNA (Patisiran) 및 mRNA (COVID-19 백신) 약물에 사용 된 지질 나노 입자 기술의 차이Review Published on 2021-12-012022-08-31 Journal: Drug metabolism and pharmacokinetics [Category] MERS, 치료제, [키워드] approval approved approved drug biodistribution Candidates coronavirus disease Coronavirus disease 2019 COVID-19 COVID-19 vaccine COVID-19 vaccine moderna difference drug drugs effective delivery Elasomeran Genes Ionizable lipid Lipid Lipid nanoparticles LNP Medicine Moderna mRNA mRNA vaccine mRNA vaccines mRNA-based Onpattro outbreak Patisiran Pfizer-BioNTech provided remained Safe SARS-CoV-2 siRNA target cell target cells Tozinameran translation [DOI] 10.1016/j.dmpk.2021.100424 PMC 바로가기 [Article Type] Review
Lung squamous cell carcinoma with hemoptysis after vaccination with tozinameran ( BNT162b2 , Pfizer‐BioNTech )Case Report Published on 2021-10-062022-10-28 Journal: Thoracic cancer [Category] COVID-19, [키워드] Abnormalities adverse event atezolizumab benefit bleeding BNT162b2 Brain bronchoscopy Cancer Cell cerebral hemorrhage Coagulation condition coronavirus disease discharged exceeded had no hemoptysis hemorrhagic event initiated intensive care Intubated lung cancer Patient Pfizer‐BioNTech Radiation Radiotherapy receiving reported risk second dose the patient therapy thrombosis Tozinameran tracheal vaccination Vaccine vasculature was performed [DOI] 10.1111/1759-7714.14179 PMC 바로가기 [Article Type] Case Report
Tozinameran (BNT162b2) Vaccine: The Journey from Preclinical Research to Clinical Trials and AuthorizationTozinameran (BNT162B2) 백신 : 전임상 연구에서 임상 시험 및 승인으로의 여정Review Published on 2021-06-072022-08-31 Journal: AAPS PharmSciTech [Category] MERS, SARS, 신약개발, 임상, 진단, [키워드] Administered administration adolescents adverse effects age antibody Antibody Response authorization bind BioNTech BNT162b1 BNT162b2 BNT162b2 vaccine BNT162b2 vaccines children clinical clinical trial clinical trials COVID-19 dosages Efficacy ENCODE EUA exhibited expected expression first dose host cells immune response Immunity individual Lipid nanoparticle Lipid nanoparticles mRNA Neutralizing antibodies of BNT162b2 Older operation participant Pfizer Pfizer-BioNTech Phase 1 phase 1 trials phase 1/2 trials Phase 2 phase 2 trials phase 2/ 3 trials phase 2/3 Phase 3 Phase 3 trials Preclinical preclinical studies preclinical trials pregnant pregnant women question real-world outcomes receive reported RNA robust S antigen Safety SARS-CoV-2 SARS-CoV-2 spike protein speed Spike protein Support the SARS-CoV-2 Tozinameran transfer Trial Vaccine [DOI] 10.1208/s12249-021-02058-y PMC 바로가기 [Article Type] Review